Cepheid (NASDAQ:CPHD) received CE-IVD mark for its Xpert TV molecular test for identifying Trichomoniasis infections in both men and women. The test, which has been launched in Europe, is Cepheid's nineteenth assay to get the CE-IVD mark. Trichomoniasis is one of the most common non-viral sexually transmitted diseases. The infection is caused by the protozoan parasite Trichomonas vaginalis ("TV"). According to WHO, an estimated 160 million TV infections are acquired worldwide each year, although only about 30% of infected individuals develop any symptoms.
With an estimated 7.4 million new cases of Trichomoniasis occurring each year in men and women, it is emerging as a risk factor for sexual transmission of HIV. Although women are most often affected by this disease, men can also become infected and pass the infection to their partners. TV infections are likely to disrupt the urogenital epithelia and enhance HIV replication.
The Xpert TV test will run on Cepheid's GeneXpert System, the world's leading molecular diagnostic platform with more than 7,000 systems installed worldwide. In my original analysis, I said that Cepheid has a broad range of tests that runs on its GeneXpert System across infectious diseases, hospital acquired infections ("HAI"), women's health, genetics and oncology. Xpert TV is the latest addition that will run on GeneXpert.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.